The antitumor activity of an anti-CD22 immunotoxin in SCID mice with disseminated Daudi lymphoma is enhanced by either an anti-CD19 antibody or an anti-CD19 immunotoxin
- PMID: 1384801
The antitumor activity of an anti-CD22 immunotoxin in SCID mice with disseminated Daudi lymphoma is enhanced by either an anti-CD19 antibody or an anti-CD19 immunotoxin
Abstract
The antitumor activities of immunotoxins (ITs) constructed with deglycosylated ricin A chain (dgA) and either anti-CD19 (HD37) or anti-CD22 (RFB4) monoclonal antibodies were compared in SCID mice with disseminated human Daudi lymphoma (SCID/Daudi). As reported previously, after intravenous injection with Daudi cells, SCID mice develop disseminated lymphoma, which infiltrates the vertebral column and causes paralysis of the hind legs before death. The mean paralysis time (MPT) has been taken as an end point in this tumor model. We have previously reported that early treatment of SCID/Daudi mice with RFB4 coupled to dgA prolongs the MPT in a manner consistent with the killing of 4 logs of tumor cells. In the present study, we show that HD37-dgA kills 2 logs of tumor cells. The lower potency of the HD37-dgA is consistent with its lower IC50 on Daudi cells in vitro. We further show that the antitumor activity of a mixture of HD37-dgA and RFB4-dgA is significantly enhanced in SCID/Daudi mice and is consistent with the killing in excess of 5 logs of tumor cells. However, identical enhancement was observed when a mixture of the RFB4-dgA and the HD37 antibody was administered. In contrast, enhancement was not observed when mice were injected with a mixture of the RFB4 antibody and the HD37-dgA. The results indicate that a "cocktail" of HD37 antibody and RFB4-dgA immunotoxin can have significant antitumor activity in this mouse model of lymphoma and suggest that combinations of particular antibodies and ITs may have cooperative antitumor activity.
Similar articles
-
Antitumor activity of Fab' and IgG-anti-CD22 immunotoxins in disseminated human B lymphoma grown in mice with severe combined immunodeficiency disease: effect on tumor cells in extranodal sites.Cancer Res. 1991 Nov 1;51(21):5876-80. Cancer Res. 1991. PMID: 1933855
-
A phase I study of combination therapy with immunotoxins IgG-HD37-deglycosylated ricin A chain (dgA) and IgG-RFB4-dgA (Combotox) in patients with refractory CD19(+), CD22(+) B cell lymphoma.Clin Cancer Res. 2000 Apr;6(4):1302-13. Clin Cancer Res. 2000. PMID: 10778955 Clinical Trial.
-
Treatment of SCID/human B cell precursor ALL with anti-CD19 and anti-CD22 immunotoxins.Leukemia. 2003 Feb;17(2):334-8. doi: 10.1038/sj.leu.2402790. Leukemia. 2003. PMID: 12592332
-
Specifically targeting the CD22 receptor of human B-cell lymphomas with RNA damaging agents.Crit Rev Oncol Hematol. 2001 Jul-Aug;39(1-2):79-86. doi: 10.1016/s1040-8428(01)00116-0. Crit Rev Oncol Hematol. 2001. PMID: 11418304 Review.
-
Antibody targeted therapeutics for lymphoma: new focus on the CD22 antigen and RNA.Expert Opin Biol Ther. 2001 Nov;1(6):995-1003. doi: 10.1517/14712598.1.6.995. Expert Opin Biol Ther. 2001. PMID: 11728231 Review.
Cited by
-
Immunotoxins for the treatment of B-cell lymphomas.Mol Med. 1997 Jul;3(7):420-7. Mol Med. 1997. PMID: 9260154 Free PMC article. Review. No abstract available.
-
An anti-CD30 single-chain Fv selected by phage display and fused to Pseudomonas exotoxin A (Ki-4(scFv)-ETA') is a potent immunotoxin against a Hodgkin-derived cell line.Br J Cancer. 1999 Jun;80(8):1214-22. doi: 10.1038/sj.bjc.6690488. Br J Cancer. 1999. PMID: 10376974 Free PMC article.
-
Linked-in: design and efficacy of antibody drug conjugates in oncology.Oncotarget. 2013 Mar;4(3):397-412. doi: 10.18632/oncotarget.924. Oncotarget. 2013. PMID: 23651630 Free PMC article.
-
Antitumor activity of immunotoxins with T-cell receptor-like specificity against human melanoma xenografts.Cancer Res. 2008 Aug 1;68(15):6360-7. doi: 10.1158/0008-5472.CAN-08-0928. Cancer Res. 2008. PMID: 18676861 Free PMC article.
-
A comparison of the anti-tumor effects of a chimeric versus murine anti-CD19 immunotoxins on human B cell lymphoma and Pre-B acute lymphoblastic leukemia cell lines.Toxins (Basel). 2011 Apr;3(4):409-19. doi: 10.3390/toxins3040409. Epub 2011 Apr 6. Toxins (Basel). 2011. PMID: 22069716 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials